TScan Therapeutics TCRX
NASDAQ TCRX
$0.32 +0.00 (+0.95%)
At close: Oct 1, 2026 · 4:00 PM EDT

TScan Therapeutics (TCRX) Preferred Stock Liabilities (2020 - 2021)

Updated

TScan Therapeutics (TCRX) reported Preferred Stock Liabilities of $159.41 million for Q2 2021, up 167.1% from $59.68 million a year earlier and unchanged from the prior quarter.

Analysis

TScan Therapeutics (TCRX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

At the end of FY2020, TScan Therapeutics posted Preferred Stock Liabilities of $59.68 million.

  • Per Business Quant data, the three quarters before Q2 2021 came in at $159.41 million (Q1 2021), $59.68 million (Q4 2020) and $59.68 million (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 TScan Therapeutics 40.28 Mn 40.28 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 159.41 Mn
Mar 31, 2021 159.41 Mn
Dec 31, 2020 59.68 Mn
Sep 30, 2020 59.68 Mn
Jun 30, 2020 59.68 Mn
API Access

TScan Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=TCRX&period=max&api_key=YOUR_API_KEY